Somnomed Limited · ASX:SOM
Somnomed — H1 FY2020 Earnings Presentation
25 slides from Somnomed's earnings presentation, Feb 18, 2020
Slide 1: Investor Presentation Half Year FY2020
For personal use only Investor Presentation Half Year FY2020
Slide 2: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Treatment focused, Technology driven
For personal use only Treatment focused Technology driven
Slide 4: For personal use only
For personal use only 1.First-half results summary 2.Vision & market opportunity 3.Financial information 4.Future horizons update 5.Outlook & guidance FY20
Slide 5: 1. First-half results summary
For personal use only 1. First-half results summary
Slide 6: First-half summary
First-half summary For personal use only SomnoMed’s core revenue growth +15% over prior year Successful launch of the digital SomnoDent® Avant EBITDA* $3m and +130% over prior year Key strategic contract signed with App-Nea LLC North America first-half revenue growth +26% and Medical survey conducte
Slide 7: 2. Vision & market opportunity
For personal use only 2. Vision & market opportunity
Slide 8: Vision/Mission
Vision/Mission For personal use only Vision: SomnoMed will be a leader in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Mission: Advancing the adoption and acceptance of the treatment therapies by medical specialists, dentists, patients and insurer
Slide 9: Obstructive Sleep Apnea
SOMNOMED Obstructive Sleep Apnea For personal use only Obstructive sleep apnea is a disorder that occurs when a person’s breathing is interrupted during sleep because the airway becomes blocked 9 https://somnomed.com 9
Slide 10: OSA Market
OSA MARKET 1.36 billion patients globally suffer with OSA* For personal use only Affects 9% of women and 25% of men globally Large addressable markets: 54m mild OSA sufferers Moderate & severe 26m mild OSA sufferers OSA 400m. patients 23m mild OSA sufferers Mild OSA 936m. patients 22m mild OSA suffe
Slide 11: SomnoMed's competitive advantage and core strengths
SomnoMed’s competitive advantage and core strengths For personal use only Strong clinical research supporting COAT™ therapy Design and innovation driving patient comfort Comprehensive product range Proprietary materials Unique titration methodology (SomnoDent® Avant) Manufacturing agility and capaci
Slide 12: The patient preferred alternative
The patient preferred alternative For personal use only SomnoMed is the world leader in oral appliances with over 545,000 patients treated worldwide https://somnomed.com https://somnomed.com 12
Slide 13: 3. Financial information
For personal use only 3. Financial information
Slide 14: Total SomnoMed core revenue growth
Financials For personal use only Total SomnoMed core revenue growth https://somnomed.com https://somnomed.com 14
Slide 15: Core revenue growth by region
Financials For personal use only Core revenue growth by region https://somnomed.com https://somnomed.com 15
Slide 16: MAS device margin maintained
Financials For personal use only MAS device margin maintained https://somnomed.com https://somnomed.com 16
Slide 17: Strong EBITDA growth
Financials For personal use only Strong EBITDA growth * EBITDA as adjusted does not include share and option expense, loss on contingent consideration payable and unrealised foreign exchange gain/(loss) https://somnomed.com https://somnomed.com 17
Slide 18: Financial Summary - AUD $000's SomnoMed core
Financial Summary - AUD $000's SomnoMed core FY20 HY FY19 HY % Sales and Marketing costs Revenue 33,256 28,815 15% 1. 8.5% due to increased Sales and Marketing field presence in the United For personal use only Gross margin 19,458 17,018 14% States and Europe; 2. 6.5% related to medical research in
Slide 19: Summary Balance Sheet and Cash Flow
Summary Balance Sheet and Cash Flow Statement of financial position - AUD $m. Statement of cash flows - AUD $m. FY20 HY FY19 HF 31.12.19 30.06.19 For personal use only EBITDA* CORE 3.0 1.3 Cash and cash equivalents 8.9 7.7 EBITDA* RSS** - (7.0) Inventories 2.3 1.9 EBITDA* GROUP 3.0 (5.7) Trade and o
Slide 20: 4. Future horizons - update
For personal use only 4. Future horizons - update
Slide 21: Our future horizons
Our future horizons For personal use only Advancing treatment Positioning “the Technology & building the core patient’s alternative” driven Sales and marketing focus and Effective medical outcome of Digital manufacturing investment globally COAT™ versus CPAP Technology bridge through Medical researc
Slide 22: 5. Outlook & guidance
For personal use only guidance 5. Outlook &
Slide 23: Outlook & guidance
Outlook & guidance For personal use only Regional Europe – market fundamentals for consistent revenue growth remain solid, focusing on a stronger reimbursement policy and medical strategy North America – maintain direct revenue growth momentum through product and service differentiation, while build
Slide 24: Treatment focused, Technology driven
For personal use only Treatment focused Technology driven
Slide 25: Contact
Contact For personal use only Chief Executive Officer: Mr Neil Verdal-Austin Chief Financial Officer: Mr Hervé Fiévet Address: 20 Clarke Street, Crows Nest, Sydney 2065 Telephone: 02 9467 0400 Website: www.somnomed.com